メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
東北大学 ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
プレス/メディア
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
Tarasawa Kunio
准教授
医学系研究科・公衆衛生学専攻
h-index
278
被引用数
9
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2020
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(52)
プレス/メディア
(5)
類似のプロファイル
(6)
フィンガープリント
Kunio Tarasawaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Acute Pancreatitis
42%
Analgesia
29%
Biological Product
26%
Bleeding
51%
Cohort Analysis
20%
Colorectal Carcinoma
15%
Comorbidity
16%
Congestive Heart Failure
28%
Cost-Effectiveness Analysis
42%
Crohn's Disease
28%
Deep Vein Thrombosis
14%
Disease Activity
32%
Disease Course
27%
Disseminated Intravascular Coagulation
17%
Elderly Patient
57%
Endoscopic Submucosal Dissection
50%
Health Care Cost
38%
Hemoperfusion
42%
Hip Fracture
57%
Hospital Mortality
55%
Inflammatory Arthritis
28%
Inflammatory Bowel Disease
38%
Infliximab
18%
Intensive Care Unit
42%
Logistic Regression Analysis
35%
Malignant Neoplasm
17%
Mortality Rate
29%
Multivariate Analysis
17%
Neuromyelitis Optica
28%
Noradrenalin
16%
Observational Study
100%
Odds Ratio
79%
Patient with Crohn's Disease
26%
Patient with Inflammatory Bowel Disease
25%
Patient with Ulcerative Colitis
45%
Pediatrics
28%
Polymyxin B
42%
Primary Sclerosing Cholangitis
28%
Propensity Score Matching
86%
Proton-Pump Inhibitor
51%
Pulmonary Embolism
23%
Rheumatoid Arthritis
28%
Sepsis
21%
Septic Shock
30%
Sequela
21%
SOFA Score
17%
Subgroup Analysis
30%
Total Hip Arthroplasty
42%
Ulcerative Colitis
74%
Vonoprazan
53%
Pharmacology, Toxicology and Pharmaceutical Science
Antiarrhythmic Agent
14%
Atrial Fibrillation
14%
Bleeding
17%
Bone Necrosis
14%
Chemotherapy
14%
Cholangitis
14%
Cohort Study
16%
Congestive Cardiomyopathy
14%
Congestive Heart Failure
28%
Crohn's Disease
14%
Deep Vein Thrombosis
10%
Direct Oral Anticoagulant
14%
Disease Activity
14%
Diseases
26%
Disseminated Intravascular Clotting
14%
Electrolyte Disturbance
14%
Heart Infarction
18%
Hematologic Malignancy
14%
Hemoperfusion
57%
Hip Fracture
57%
Hospital Mortality
49%
Inflammatory Arthritis
14%
Kidney Disease
21%
Loop Diuretic Agent
21%
Lung Embolism
18%
Malignant Neoplasm
14%
Meningitis
14%
Multiple Sclerosis
14%
Myelooptic Neuropathy
28%
Necrosis
14%
Noradrenalin
16%
Observational Study
57%
Organ Dysfunction Score
14%
Pancreatitis
14%
Periprosthetic Joint Infection
14%
Personality Disorder
14%
Polymyxin B
57%
Prevalence
12%
Primary Sclerosing Cholangitis
14%
Proton Pump Inhibitor
37%
Rheumatoid Arthritis
14%
Sepsis
38%
Septic Shock
30%
Syndrome
14%
Thrombomodulin
14%
Tolvaptan
21%
Ulcerative Colitis
28%
Upper Gastrointestinal Bleeding
14%
Ustekinumab
14%
Vonoprazan
42%
Nursing and Health Professions
Bone Necrosis
14%
Clinical Practice
14%
Confidence Interval
19%
Congestive Heart Failure
14%
Continuous Hemodiafiltration
14%
Cost Effectiveness Analysis
14%
Elderly Patient
16%
Hematologic Malignancy
14%
Hemoperfusion
14%
Hip Fracture
14%
Hospital Readmission
15%
Incremental Cost-Effectiveness Ratio
5%
Inflammatory Arthritis
14%
Intensive Care Unit
31%
Intensivist
14%
Mortality Rate
11%
Odds Ratio
15%
Osteoarthritis
6%
Patient with Ulcerative Colitis
7%
Polymyxin B
14%
Propensity Score
7%
Quality Adjusted Life Year
6%
Rheumatoid Arthritis
14%
Sepsis
14%
Total Hip Prosthesis
14%
Ulcerative Colitis
14%
